These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23532731)

  • 1. Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor?
    Giuliani J; Marzola M
    J Gastrointest Cancer; 2013 Jun; 44(2):241-5. PubMed ID: 23532731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
    Su X; Lacouture ME; Jia Y; Wu S
    Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?
    Giuliani J; Marzola M
    Arch Dermatol Res; 2013 Sep; 305(7):653-8. PubMed ID: 23536039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience.
    Giuliani J; Indelli M; Marzola M; Raisi E; Frassoldati A
    Tumori; 2012; 98(4):408-12. PubMed ID: 23052154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17.
    Sommeijer DW; Karapetis CS; Zalcberg JR; Tu D; Jonker DJ; Simes J; Tebbutt N; Yip D; Price TJ; O'Callaghan CJ
    Acta Oncol; 2014 Jul; 53(7):877-84. PubMed ID: 24495042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Crit Rev Oncol Hematol; 2015 Feb; 93(2):127-35. PubMed ID: 25139841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer.
    Pinta F; Ponzetti A; Spadi R; Fanchini L; Zanini M; Mecca C; Sonetto C; Ciuffreda L; Racca P
    Clin Colorectal Cancer; 2014 Mar; 13(1):62-7. PubMed ID: 24332355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
    Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
    Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.
    Orditura M; De Vita F; Galizia G; Lieto E; Vecchione L; Vitiello F; Martinelli E; Ciardiello F
    Oncol Rep; 2009 Apr; 21(4):1023-8. PubMed ID: 19288004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials.
    Petrelli F; Borgonovo K; Barni S
    Target Oncol; 2013 Sep; 8(3):173-181. PubMed ID: 23321777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients.
    Cignola S; Gonella S; Alessandra B; Palese A
    Eur J Oncol Nurs; 2016 Feb; 20():133-9. PubMed ID: 26187661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and management of cutaneous toxicities associated with cetuximab.
    Saif MW; Kim R
    Expert Opin Drug Saf; 2007 Mar; 6(2):175-82. PubMed ID: 17367263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients.
    Romito F; Giuliani F; Cormio C; Tulipani C; Mattioli V; Colucci G
    Support Care Cancer; 2010 Mar; 18(3):329-34. PubMed ID: 19484487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients.
    Saridaki Z; Tzardi M; Papadaki C; Sfakianaki M; Pega F; Kalikaki A; Tsakalaki E; Trypaki M; Messaritakis I; Stathopoulos E; Mavroudis D; Georgoulias V; Souglakos J
    PLoS One; 2011 Jan; 6(1):e15980. PubMed ID: 21283802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
    Hofheinz RD; Lorenzen S; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Tetyusheva M; Heeger S; Vlassak S; Merx K
    Ann Oncol; 2018 Apr; 29(4):1010-1015. PubMed ID: 29360920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cetuximab in combination with chemotherapy for patients with gastrointestinal cancer].
    Zhang XT; Shen L; Zhang XD; Li J; Zhang ZT
    Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):385-8. PubMed ID: 18953842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
    Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
    Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical predictors of response to cetuximab-chemotherapy in metastatic colorectal cancer.
    Ma AT; Ma BB; Lei KI; Mo FK; Chan AT
    Hong Kong Med J; 2010 Jun; 16(3):207-12. PubMed ID: 20519757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
    Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.